The quiet has been telling. Since Nel ASA published its second-quarter numbers on July 15, the Norwegian hydrogen specialist has gone radio-silent — no fresh orders, no business updates, no guidance tweaks. The shares, meanwhile, have drifted to €0.2025, down 2.2% on the day, with the stock hovering roughly 43% below its May peak of €0.3655.
That lull is precisely what makes the coming weeks uncomfortable. The market has already clawed back much of the spring’s recovery optimism, and the next quarterly report — due October 21 — will determine whether Nel’s recent order surge was a genuine inflection point or a statistical blip.
The Conversion Bottleneck
Strip away the noise and one question dominates: how quickly can Nel turn its backlog into billed revenue? The order book stood at NOK 1.213 billion at the end of the second quarter, with the PEM electrolyser division accounting for the bulk of recent intake — 96% of new orders landed there. The PEM backlog alone swelled by NOK 147 million to NOK 990 million.
But here’s the rub. PEM revenue came in at NOK 97 million for the quarter — down 10% year-on-year, even if the 31% sequential jump offered a flicker of encouragement. The gap between order intake and recognized sales is the single most important metric to watch over the next two to three quarters. If that conversion accelerates, the capacity expansion story holds together. If it stalls, Nel risks building plant that sits idle, tying up capital the company can ill afford to waste.
The Bull Case: Momentum That Looks Real
Optimists can point to numbers that are hard to dismiss. Order intake jumped 171% quarter-on-quarter and 224% year-on-year to NOK 230 million — a pace that suggests the demand trough may be behind the company. The commercial launch in May of the next-generation pressurized alkaline platform broadens the product offering, and the PEM segment’s EBITDA improved by NOK 12 million sequentially, even if it remains negative at minus NOK 35 million.
There’s also evidence that the order flow isn’t a one-off. In April, Nel Hydrogen US secured a roughly $7 million order from a public utility for PEM equipment, with a second contract of similar size from Mesure Process for a European project arriving days earlier. Recurring customer relationships of this sort carry more weight than a single headline order.
Add to that a signal from the boardroom: chairman Arvid Moss purchased 100,000 Nel shares in April at an average price of NOK 2.2547 — a modest but visible vote of confidence from the top.
Should investors sell immediately? Or is it worth buying Nel ASA?
With a cash position of NOK 1.3 billion, Nel has the runway to fund its expansion plans in the near term. And if the PEM demand materializes as the order book suggests, the current market capitalization of around €377 million could start to look thin. The stock is trading just above its 52-week low of €0.1731, and believers argue that the pessimism is already fully priced in.
The Bear Case: Orders Aren’t Revenue
The counter-argument is equally straightforward. Group revenue fell 12% year-on-year to NOK 153 million, and EBITDA landed at minus NOK 155 million — a figure that includes a NOK 70 million settlement payment related to the Iwatani dispute. Strip out that one-off, and the underlying operations are still deeply loss-making.
The alkaline business, meanwhile, contracted 14% year-on-year, underscoring that the demand recovery is lopsided. A growing dependence on PEM alone carries concentration risk, and an order book is not the same as cash in the bank. Delays in equipment delivery — whether from supply chain snags or customer-side project postponements — would push the earnings improvement further out.
Chart watchers note the shares are hovering near the 50-day moving average of around €0.2137, with the current price dipping below that level. The stock sits 4.4% under its 50-day average and 5.5% below the 200-day line — technical signals that the market is treating the medium-term story with skepticism rather than enthusiasm.
The October Test
The capacity expansion roadmap — 500 megawatts by end-2026, doubling to 1 gigawatt in 2027 — is backed by a €135 million grant from the EU Innovation Fund. That support removes some financing risk, but it doesn’t guarantee demand will fill the factories.
The third-quarter report on October 21 will provide the first real evidence. If the order momentum from Q2 carries through and, crucially, starts showing up in revenue, Nel’s argument for building capacity ahead of demand gains credibility. If the conversion remains sluggish, the 500-megawatt milestone becomes a balance-sheet burden rather than a growth catalyst.
Between now and then, the stock is likely to oscillate within the range defined by its 52-week low and the considerably higher annual peak — a technical reflection of the fundamental uncertainty. The bull and bear cases are both coherent; the difference lies in whether the order book is a leading indicator or a lagging mirage.
Ad
Nel ASA Stock: Buy or Sell?! New Nel ASA Analysis from August 13 delivers the answer:
The latest Nel ASA figures speak for themselves: Urgent action needed for Nel ASA investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 13.
Nel ASA: Buy or sell? Read more here...
